3E Bioventures

What 3E Bioventures does

3E Bioventures Capital is a privately-held venture capital firm founded in 2015 that invests in life-science companies across two pillars: Biotech (new drugs, new modalities, and drug discovery platforms) and TechBio (the intersection of biology and technology). The firm is headquartered at 228 Hamilton Ave, 3rd floor, Palo Alto, California, and maintains a Chinese-registered legal entity (ICP filing 京ICP备16004239号), giving it a cross-border sourcing footprint across US biotech hubs and China-originated assets. Its stated motto is "Expertise, Efficiency, Execution," and it pursues a science-driven, entrepreneur-friendly investment philosophy, working closely with founders and research institutions to back drugs and platforms addressing high unmet medical need. The active portfolio includes 30+ companies spanning oncology, CNS, ophthalmology, dermatology, rare disease, and platform technologies, with multiple Nasdaq-listed holdings including Aravive (ARAV), C4 Therapeutics (CCCC), Cognition Therapeutics (CGTX), Cytek (CTKB), and Twist Bioscience (TWST).

The firm generates revenue through the standard venture-capital model: management fees on committed capital plus carried interest on successful portfolio exits (IPOs, M&A, secondaries). Its core technology is its investment-process infrastructure — a thesis-driven sourcing engine built on scientific advisory networks, industry conference participation, and research-institution partnerships — rather than any proprietary product platform. Notable portfolio bets illustrate the thesis: Cullgen and C4 Therapeutics in targeted protein degradation, OncoC4 in immuno-oncology (CTLA-4 and CD24 antibodies), Lysoway Therapeutics in lysosomal ion channel disease biology (with the first TRPML1 agonist in clinical development), Subtle Medical in AI-powered medical imaging (FDA-cleared and recipient of a $33M growth round in June 2026), Dewpoint Therapeutics in condensate biology, and Twist Bioscience in silicon-based DNA synthesis. Leadership disclosed in the data is limited to founding partner Karen Liu and vice president Lue Sun, with broader management-team detail not available.

Customer-facing activity is relationship-driven rather than transactional: the fund engages directly with biotech and TechBio founders, co-invests with strategic and institutional partners, and sources deals through conference presence, research-institution ties, and referrals. Pricing and fund terms are privately negotiated with limited partners and are not publicly disclosed.

Name

3E Bioventures

Legal name

3E Bioventures Capital

Website

https://3ebiovc.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

3E Bioventures Capital is a privately-held life-science venture capital firm founded in 2015, headquartered in Palo Alto with a China-registered entity, investing across Biotech and TechBio. It backs 30+ portfolio companies — including multiple Nasdaq-listed names — developing new drugs, novel modalities, and biology-technology platforms addressing unmet medical needs.

Ownership category

akta.pro rank

Product category

Venture Capital (Life Sciences)

NAICS

Other Investment Pools and Funds (5259), Other Financial Investment Activities (5239)

SIC

Investment Advice (6282)

akta.pro industry

PRIMARYFSANACAB

Healthcare & Life Sciences Growth Equity

Financial & Insurance/Private Equity & Venture Capital/Growth Equity Firms

SECONDARYFSANAAAC

Late-Stage Venture Capital (Series C+)

Financial & Insurance/Private Equity & Venture Capital/Venture Capital Firms

Keywords

• Venture capital funding
• Life science investing
• Biotech investment
• Techbio venture capital
• Growth capital

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Investment Management Fees and Carried Interest: As a life science VC fund, 3E Bioventures generates returns through management fees on committed capital and carried interest (performance fees) on successful portfolio company exits including IPOs, acquisitions, and secondary transactions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

3E Bioventures Capital is a life science focused venture capital fund that actively invests in global leading health innovators in Biotech (new drugs, new modalities, and drug discovery platforms) and TechBio — the intersection of biology and technology that can potentially disrupt old paradigms. The firm provides venture capital funding, strategic guidance, and operational support to early to mid-stage life science companies, working closely with companies and research institutions to develop drugs and products addressing strong unmet medical needs.

Product overview

3E Bioventures Capital is a life science-focused venture capital fund, not a product company. It does not offer commercial products or services. The firm invests in Biotech (new drugs, new modalities, and drug discovery platforms) and TechBio companies through its portfolio. Its portfolio includes biotech companies such as Aravive (AXL-Fc fusion protein for cancer), C4 Therapeutics (targeted protein degradation), Cognition Therapeutics (CNS disorders), OncoC4 (CTLA-4 and CD24 antibodies), and others, as well as health tech companies including Cytek (flow cytometry), Twist Bioscience (DNA synthesis), Subtle Medical (AI-powered medical imaging), and various other diagnostic, therapeutic, and digital health companies.

Differentiator

Problem solved

Functional benefit

Products and services

• Life Science Venture Capital Fund

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• OrbiMed: One of the largest dedicated healthcare and life science investment firms globally, investing across stages in therapeutics, medtech, and diagnostics — the closest direct comparable to 3E Bioventures' biotech/TechBio mandate.
• ARCH Venture Partners: Pioneer life science VC firm backing early-stage biotech companies developing first-in-class therapeutics from university and research institution spinouts — directly comparable to 3E's science-driven, research-anchored investment model.
• Versant Ventures: Healthcare-focused VC with deep expertise in biotech company creation and novel therapeutics across modalities — a closely comparable specialist life science investor with similar stage profile and modality breadth.
• Atlas Venture: Early-stage life science VC that builds biotech companies around innovative science, frequently partnering with academic founders on novel modalities — analogous to 3E's biotech/TechBio thesis and entrepreneur-friendly approach.
• 5AM Ventures: Early-stage life science VC focused on building biotech companies around breakthrough science, with similar emphasis on platform technologies and founder collaboration.
• Flagship Pioneering: Bioplatform innovation company that creates and funds first-in-category therapeutics and TechBio ventures — directly comparable in modality ambition and new-paradigm orientation.
• RA Capital Management: Healthcare-focused crossover fund investing across public and private biotech, including novel modalities — comparable in its life science focus and stage-agnostic deployment.

Regional players

• Qiming Venture Partners: Leading China-based VC with dedicated healthcare practice backing biotech and medtech companies — the closest regional comparable to 3E's Chinese origins and cross-border orientation.
• LYFE Capital: Healthcare-focused VC investing in biotech and medical devices with cross-border US-China reach — comparable in scope of therapeutic focus and bi-regional deal flow.

Broad incumbents

• Andreessen Horowitz Bio + Health: Major generalist VC with dedicated bio + health fund targeting biotech and digital health, including TechBio and AI-enabled drug discovery — a broader but overlapping investor in the same categories 3E targets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/3e-bioventures-capital

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments69 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 3E Bioventures